Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors

Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD). No liver injury has been observed with tolvaptan treatment in healthy subjects and in non-ADPKD indications, but ADPK...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Toxicol Sci
Auteurs principaux: Woodhead, Jeffrey L., Brock, William J., Roth, Sharin E., Shoaf, Susan E., Brouwer, Kim L.R., Church, Rachel, Grammatopoulos, Tom N., Stiles, Linsey, Siler, Scott Q., Howell, Brett A., Mosedale, Merrie, Watkins, Paul B., Shoda, Lisl K.M.
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2017
Sujets:
Mechanisms of Tolvaptan-Induced Liver Injury
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5216653/
https://ncbi.nlm.nih.gov/pubmed/27655350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/toxsci/kfw193
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires